Literature DB >> 11503003

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus.

G T Tucker1, J B Houston, S M Huang.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11503003     DOI： 10.1067/mcp.2001.116891

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  21 in total

1.  Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.

Authors:  Jasper Dingemanse; Dieter Schaarschmidt; Paul L M van Giersbergen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.

Authors:  G E Blakey; J A Lockton; J Perrett; P Norwood; M Russell; Z Aherne; J Plume
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

3.  Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Authors:  Evan D Kharasch; Pamela Sheffels Bedynek; Christine Hoffer; Alysa Walker; Dale Whittington
Journal:  Anesthesiology       Date:  2012-02       Impact factor: 7.892

4.  Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.

Authors:  Erik Mogalian; Polina German; Brian P Kearney; Cheng Yong Yang; Diana Brainard; John McNally; Lisa Moorehead; Anita Mathias
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

5.  The effect of erythromycin on the pharmacokinetics of rosuvastatin.

Authors:  K J Cooper; P D Martin; A L Dane; M J Warwick; A Raza; D W Schneck
Journal:  Eur J Clin Pharmacol       Date:  2003-04-01       Impact factor: 2.953

Review 6.  Application of pharmacological approaches to plant-mammal interactions.

Authors:  Jennifer S Sorensen; Michele M Skopec; M Denise Dearing
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

7.  Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.

Authors:  E D Kharasch; D Whittington; D Ensign; C Hoffer; P S Bedynek; S Campbell; K Stubbert; A Crafford; A London; T Kim
Journal:  Clin Pharmacol Ther       Date:  2012-03-07       Impact factor: 6.875

8.  Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.

Authors:  Yanfeng Wang; Li Zhou; Catherine Dutreix; Elisabeth Leroy; Qi Yin; Venkat Sethuraman; Gilles-Jacques Riviere; Ophelia Q P Yin; Horst Schran; Zhi-Xiang Shen
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

9.  Comparative studies of the effects of two novel sugar drug candidates on the CYP 1A2 and CYP 2E1 enzymes in different sexed rats using a "cocktail" approach.

Authors:  Jie Shi; Mei-Yu Geng; Chang-Xiao Liu
Journal:  Molecules       Date:  2004-11-30       Impact factor: 4.411

10.  The influence of a newly developed quinolone: antofloxacin, on CYP activity in rats.

Authors:  Xiao Xu; Hai-Yan Liu; Li Liu; Lin Xie; Xiao-Dong Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jan-Mar       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.